- Home
- IVVD vs ACHV Comparison
IVVD vs ACHV Comparison
Compare IVVD & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- ACHV
- Stock Information
- Founded
- IVVD 2020
- ACHV N/A
- Country
- IVVD United States
- ACHV Canada
- Employees
- IVVD N/A
- ACHV N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IVVD Health Care
- ACHV Health Care
- Exchange
- IVVD Nasdaq
- ACHV Nasdaq
- Market Cap
- IVVD 69.0M
- ACHV 72.5M
- IPO Year
- IVVD 2021
- ACHV N/A
- Fundamental
- Price
- IVVD $0.93
- ACHV $3.90
- Analyst Decision
- IVVD Strong Buy
- ACHV Strong Buy
- Analyst Count
- IVVD 3
- ACHV 3
- Target Price
- IVVD $5.85
- ACHV $14.33
- AVG Volume (30 Days)
- IVVD 3.1M
- ACHV 247.2K
- Earning Date
- IVVD 05-15-2025
- ACHV 05-13-2025
- Dividend Yield
- IVVD N/A
- ACHV N/A
- EPS Growth
- IVVD N/A
- ACHV N/A
- EPS
- IVVD N/A
- ACHV N/A
- Revenue
- IVVD $36,688,000.00
- ACHV N/A
- Revenue This Year
- IVVD $606.63
- ACHV N/A
- Revenue Next Year
- IVVD $83.30
- ACHV N/A
- P/E Ratio
- IVVD N/A
- ACHV N/A
- Revenue Growth
- IVVD N/A
- ACHV N/A
- 52 Week Low
- IVVD $0.35
- ACHV $1.84
- 52 Week High
- IVVD $2.74
- ACHV $5.58
- Technical
- Relative Strength Index (RSI)
- IVVD 63.94
- ACHV 74.55
- Support Level
- IVVD $0.81
- ACHV $2.89
- Resistance Level
- IVVD $1.00
- ACHV $3.32
- Average True Range (ATR)
- IVVD 0.12
- ACHV 0.27
- MACD
- IVVD 0.02
- ACHV 0.09
- Stochastic Oscillator
- IVVD 64.76
- ACHV 98.69
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.